(EBP-001 (GR-007)) Retrospective Descriptive Analysis of Transforming Powder Dressing in 70 Patients with Hard-To-Heal Wounds

Natalia Kirsten, MD – Comprehensive Wound Center, University Medical Center of Hamburg; Susan Rolniak St. John, MSN, APRN-NP – Wound Care Consultant, Altrazeal Life Sciences Inc.; Sandra Wolf, MSc – German Institute for Health Services Research in Dermatology and Nursing

Introduction:

Wound healing outcomes are confounded by multiple systemic and environmental factors which can complicate and delay overall progression. Rising wound management costs are driving the search for new treatment paradigms that can be more safe, efficacious, and cost effective while reducing the burden of care.

Methods:

Seventy (70) patients diagnosed with hard-to-heal wounds which were refractory to Standard of Care (SOC) and categorized as vulnerable patients with respect to wound healing progression were referred to our University-based German wound clinic that specializes in the treatment of severe recalcitrant chronic wounds clinic and converted from SOC to Transforming Powder Dressing (TPD). Data was collated and final results for incidence of wound healing were compared to a matching cohort of data from the European Wound Registry (EWR) for SOC wound treatment. SOC was based on the local European guidelines for treatment of chronic wounds.

Prior to conversion to TPD, wound duration was a mean of 19.1 months (maximum duration: 240 months). The mean age of the cohort was 65.3 years (range: 23-96).  Gender distribution was 29 male (41%)  and 41 female (59%). Wound etiologies included 23 venous ulcers (33%), 18 atypical wounds (26%), 10 traumatic/post-surgical wounds (14%), 7 diabetic foot ulcers (10%), 5 arterial ulcers (7%) and 7 other etiologies (10%).

Results:

Complete wound healing at 14 weeks was achieved in 37 TPD patients  (53%) versus 8% for SOC patients. TPD’s extended wear time of 30-days was maintained in 46 wounds (66%) of which 37 (80%) were fully healed. Accelerated reduction of wound surface areas was observed and clinical treatment goals (e.g. healing, granulation, pain reduction) were met in 50 patients (71%). No unanticipated adverse events were reported.

Discussion:

TPD was observed to be safe and effective in the treatment of a wide range of hard-to-heal wounds and to significantly accelerate healing relative to European SOC guidelines. No unanticipated adverse events were observed during extended wear time. TPD presents a promising new wound treatment strategy with potential to improve healing outcomes and the patient experience while reducing the burden of care associated with time required for dressing change relative to SOC.

Trademarked Items:

References: